Andrew Booth - Jan 14, 2024 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Financial Officer
Signature
Tryn Stimart, attorney-in-fact
Stock symbol
ABCL
Transactions as of
Jan 14, 2024
Transactions value $
$0
Form type
4
Date filed
1/16/2024, 06:18 PM
Previous filing
May 26, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share option (right to buy) Award $0 +770K +13.24% $0.00 6.59M Jan 14, 2024 Common Shares 770K $5.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.